Risk Factors, Pathogenesis, and Management of Alpha-Gal Syndrome
Medical Research Archives · 30.09.2026 · 14 (9)
DOI: 10.18103/mra.2026.0638 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, online erschienen am 30.09.2026. Verfasst von Nicolas Hulscher und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Alpha-gal syndrome (AGS) is an IgE-mediated allergy to galactose-?-1,3-galactose (alpha-gal), with suspected cases rising roughly 100-fold over the past decade and alpha-gal IgE detected in 24% of adults in high-burden U.S. states. Tick bites are the best-supported sensitizing exposure, but important uncertainties remain regarding dose, host susceptibility, and why only a minority of bitten individuals sensitize. Alpha-gal is also present in mammalian-derived gelatin used in several vaccines. More than 90% of U.S. children receive approximately 54 mg of alpha-gal-bearing gelatin parenterally before school entry, bypassing oral tolerance. We review evidence supporting two non-exclusive pathways by which vaccine-derived alpha-gal could contribute to sensitization: direct induction of alpha-gal-specific IgE and immune priming followed by tick-bite boosting. Human evidence from Japan links gelatin-containing, aluminum-adjuvanted DTaP to de novo anti-gelatin IgE and subsequent vaccine anaphylaxis, while cross-species reactivity patterns are consistent with alpha-gal recognition. In alpha-gal-deficient mice, injected alpha-gal coupled to protein with vaccine-grade aluminum adjuvant induces alpha-gal-specific IgE and anaphylaxis. Gelatin-containing vaccines also activate basophils from patients with established AGS. Direct vaccine-induced sensitization in humans remains unproven, but convergent human, immunochemical, and animal evidence warrants prospective testing of alpha-gal-specific antibodies before and after vaccination and direct quantification of alpha-gal in vaccine lots and tick saliva. Prevention should emphasize rigorous tick-bite avoidance and careful selection of mammalian-derived foods, medications, biologics, and vaccines in sensitized individuals. Management remains centered on avoidance and emergency preparedness, while mast-cell-directed botanical combinations and auricular acupuncture have shown preliminary clinical promise and warrant controlled evaluation as potential adjunctive strategies.
Zitieren
APA
Hulscher, N., Thorp, J. A., Pinsky, D., Gillooly, P., Risch, H., McCullough, P. A., & Victory, K. (2026). Risk Factors, Pathogenesis, and Management of Alpha-Gal Syndrome. Medical Research Archives, 14(9). https://doi.org/10.18103/mra.2026.0638
Vancouver
Hulscher N, Thorp JA, Pinsky D, Gillooly P, Risch H, McCullough PA, et al. Risk Factors, Pathogenesis, and Management of Alpha-Gal Syndrome. Medical Research Archives. 2026;14(9). doi:10.18103/mra.2026.0638
BibTeX
@article{Hulscher2026,
author = {Hulscher, Nicolas and Thorp, James A. and Pinsky, Drew and Gillooly, Peter and Risch, Harvey and McCullough, Peter A. and Victory, Kelly},
title = {Risk Factors, Pathogenesis, and Management of Alpha-Gal Syndrome},
journal = {Medical Research Archives},
year = {2026},
volume = {14},
number = {9},
doi = {10.18103/mra.2026.0638}
}
EUVIMED